The Latest Breaking News on Pharma

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com · Nov 29, 2024

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

StockNews.com · Nov 27, 2024

Telanagana: Spurious antibiotics worth Rs 1.33 crore seized from a pharmaceutical company

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Dynamite News · Nov 27, 2024

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Benzinga · Nov 26, 2024

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Benzinga · Nov 26, 2024

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic CancerWarns Shareholders

Benzinga · Nov 25, 2024

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga · Nov 25, 2024

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga · Nov 25, 2024

I love the ingenious design of this women’s health brand logo

Design Bridge and Partners create a pioneering brand for the future.

Creative Bloq · Nov 24, 2024

Democrats can still lower drug prices

High medication costs are a common enemy for Democrats, Republicans and patients. There's still time to fight

Salon · Nov 22, 2024